vTv Therapeutics Inc. Class A Common Stock VTVT
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $53.60 (+78.0% upside)
Key Stats
- Today's Range
- $28.76 – $31.14
- 50-Day Range
- $28.76 – $38.84
- 52-Week Range
- $14.00 – $44.00
- Volume
- 75K shs
- Average Volume
- 97K shs
- Market Cap
- $119.09 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.51
- Price / Sales
- 3.23
Short Interest
- Short Interest
- 10.46%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $36.84 million
- Net Income
- $-6,403,000
- Net Margin
- -17.38%
- Return on Equity
- -8.14%
- Debt-to-Equity
- —
About vTv Therapeutics Inc. Class A Common Stock
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Related Stocks
Compare head-to-head: VTVT vs LLY·VTVT vs JNJ·VTVT vs ABBV·VTVT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.